[{"id":"91129fdb-7ee9-4817-acf7-e8fc2da77a2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03338972","created_at":"2021-01-18T16:29:36.458Z","updated_at":"2025-02-25T14:37:39.553Z","phase":"Phase 1","brief_title":"Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT03338972","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" SDC1","pipe":" | ","alterations":" SDC1 expression","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SDC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • FCARH143 • FHVH-BCMA-T • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 11/29/2017","start_date":" 11/29/2017","primary_txt":" Primary completion: 05/03/2021","primary_completion_date":" 05/03/2021","study_txt":" Completion: 03/22/2022","study_completion_date":" 03/22/2022","last_update_posted":"2023-09-08"}]